Fertility and pregnancy outcomes in women with nonclassic 21‐hydroxylase deficiency
Authors' conclusion
Infertility is relative in patients with NCCAH. HC seems beneficial for fertility and pregnancy outcomes, especially for patients with menstrual disorders and high preconceptional androgen levels.
Study context
- Population
- Women with nonclassic CAH (21-hydroxylase deficiency) confirmed by genetic testing, followed in a referral centre 2010–201995 with parental project
- Participants
- 173 women
- Exposure
- Glucocorticoid (GC) treatment vs no GC treatment
- Outcome
- Fertility and pregnancy outcomes
Methodological detailssingle referral centre
- Single referral centre
Main finding
As reported in the abstract
- Women with pregnancies
- 86
- Pregnancies
- 176
- Pregnancies under GC treatment
- 56%
- Pregnancies without GC treatment
- 44%
- Women with live births
- 76
- Live births
- 128
- Patients who regularized their cycle under GC treatment, with significant decrease of androgens and progesterone
- Two-thirds
Observational data: associations, not effects.
Secondary outcomes
| Outcome | Coef β (CI) | P value |
|---|---|---|
| TTC with GC treatment | −.196 (−10.7 to −0.91) | P = 0.021 |
- Time to conceive (TTC) with GC treatment: shortening of TTC with GC; interval labelled information coefficient [IC]
Predictors of miscarriage
- Testosterone: OR 4.8, IC [1.15; 20.34], p = .021
- Androstenedione: OR 1.4, IC [1.05; 1.81], p = .02
- TTC: OR 1.03, IC [1.01; 1.06], p = .015
- Androgen levels and TTC positively correlated with miscarriage rate
Obstetric outcomes
- No difference in obstetric outcomes between patients with or without GC treatment
CYP21A2 genotype
- CYP21A2 genotype had no impact on pregnancy outcome or TTC
Original publication
Fertility and pregnancy outcomes in women with nonclassic 21‐hydroxylase deficiency. Clin Endocrinol (Oxf). Published 17 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →